GlassScriptPhysician profile
Katelyn Tello
NPI 1174294698
$8,348.70
in general payments reported to CMS, 2019-2025
61 companies · $986 in 2025
The $986 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $244 · 2022: $2,130 · 2023: $3,190 · 2024: $1,799 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,783 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,782.63 |
| Education | $192.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $735.66 | 2021-2025 | Adcetris, Tivdak, Tukysa |
| Novartis Pharmaceuticals Corporation | $726.85 | 2022-2025 | |
| Pfizer INC. | $580.43 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $575.30 | 2021-2024 | Imfinzi, Enhertu, Lynparza |
| Eisai INC. | $500.87 | 2022-2024 | |
| Janssen Biotech, INC. | $302.23 | 2022-2024 | Erleada, Darzalex, Imbruvica |
| Merck Sharp & Dohme LLC | $292.98 | 2021-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $277.25 | 2021-2024 | Enhertu, Injectafer |
| Genentech USA, INC. | $234.77 | 2022-2024 | Venclexta, Tecentriq, Alecensa |
| Incyte Corporation | $193.75 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $182.67 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $177.34 | 2022-2025 | Libtayo, Lynozyfic |
| Csl Behring | $171.15 | 2022-2024 | Afstyla, Idelvion |
| Apellis Pharmaceuticals, INC. | $157.00 | 2022-2024 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $156.09 | 2021-2023 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $148.26 | 2022-2023 | |
| Astellas Pharma US INC | $142.48 | 2021-2025 | Padcev, Vyloy |
| Coherus Oncology, INC. | $142.36 | 2023-2025 | Loqtorzi |
| Genmab U.S., INC. | $142.21 | 2023-2025 | Epkinly |
| Gilead Sciences, INC. | $134.36 | 2022-2024 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $130.87 | 2022-2024 | Augtyro, Krazati, Opdivo |
| Glaxosmithkline, LLC. | $128.89 | 2022-2025 | Ojjaara, Shingrix, Blenrep |
| Amgen INC. | $128.18 | 2022-2023 | Nplate, Vectibix, Xgeva |
| Servier Pharmaceuticals LLC | $106.73 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.85 | 2022-2024 | Alunbrig, Ninlaro, Iclusig |
| Abbvie INC. | $99.12 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $93.58 | 2021-2023 | Imbruvica, Epkinly |
| Tersera Therapeutics LLC | $90.44 | 2023-2025 | Quzyttir, Zoladex |
| Novocure INC. | $88.59 | 2024 | Optune Lua (Novottf-200t) |
| Janssen Scientific Affairs, LLC | $77.77 | 2022-2023 | Rybrevant, Pipeline |
| Pharmacosmos Therapeutics INC. | $71.41 | 2024-2025 | Cosela, Monoferric |
| Alexion Pharmaceuticals, INC. | $70.19 | 2023-2024 | Ultomiris |
| Stemline Therapeutics INC. | $66.50 | 2023 | Orserdu |
| Emd Serono, INC. | $65.44 | 2023-2025 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $64.96 | 2021-2024 | Onivyde |
| Array Biopharma INC | $63.09 | 2022-2023 | Mektovi, Braftovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $61.70 | 2022-2025 | Fotivda |
| Agios Pharmaceuticals, INC. | $59.46 | 2023-2025 | Pyrukynd |
| Taiho Oncology, INC. | $57.92 | 2022-2025 | |
| Puma Biotechnology, INC. | $57.49 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $57.41 | 2022 | |
| Genzyme Corporation | $57.19 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $56.64 | 2022-2023 | Tavalisse, Rezlidhia |
| Octapharma USA, INC. | $52.67 | 2022-2023 | Panzyga, Octagam Immune Globulin (Human) |
| Celgene Corporation | $45.20 | 2024 | Pomalyst, Reblozyl |
| Morphosys, US INC. | $40.01 | 2022-2023 | Monjuvi |
| Ge Healthcare | $38.65 | 2022 | |
| G1 Therapeutics, INC. | $35.56 | 2023 | Cosela |
| Dendreon Pharmaceuticals LLC | $34.90 | 2025 | Provenge |
| Kyowa Kirin, INC. | $33.15 | 2023-2024 | Poteligeo |
| Mirati Therapeutics, INC. | $32.94 | 2023-2024 | Krazati |
| Beone Medicines USA, INC. | $30.72 | 2025 | Tevimbra |
| Kite Pharma, INC. | $24.17 | 2023 | |
| Deciphera Pharmaceuticals INC. | $23.57 | 2022 | |
| Pharmaessentia USA Corporation | $21.41 | 2025 | Besremi |
| Heron Therapeutics, INC. | $21.17 | 2022-2023 | Cinvanti |
| Adc Therapeutics America, INC. | $19.24 | 2024 | |
| Blueprint Medicines Corporation | $17.78 | 2024 | Ayvakit |
| Legend Biotech USA INC. | $17.68 | 2025 | Carvykti |
| Verity Pharmaceuticals INC. | $15.09 | 2023 | Trelstar |
| Sobi, INC | $14.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Tello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.